IRWD Ironwood Pharmaceuticals Inc.

-0.19  -2%
Previous Close 11.51
Open 11.45
Price To Book -7.45
Market Cap 1761633173
Shares 155,621,305
Volume 987,181
Short Ratio
Av. Daily Volume 1,526,497

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
Olinciguat (IW-1701) - STRONG-SCD
Sickle Cell disease
Approval announced August 21, 2017.
Hyperuricemia associated with gout
Phase 2 data due 2H 2019.
IW-1973 (Praliciguat)
Diabetic nephropathy
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
Phase 3b data due mid-2019.
Irritable Bowel Syndrome with Constipation (IBS-C)
Phase 2a data released April 2016. Development to be discontinued due to disappointing data
Phase 3 data due 2H 2020.
Gastroesophageal reflux disease (GERD)
No additional trials planned.
Phase 2 data due 2H 2019.
IW-1973 (Praliciguat)
Heart failure HFpEF
Phase 2 trial to be initiated May 2019.
Irritable Bowel Syndrome
Phase 1 data due 2H 2019.
Healthy volunteers

Latest News

  1. Here's Why Ironwood Pharmaceuticals Rose as Much as 12% Today
  2. 6 Positions the Vanguard Health Care Fund Continues to Increase
  3. Edited Transcript of IRWD earnings conference call or presentation 2-May-19 12:30pm GMT
  4. Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019
  5. Did Changing Sentiment Drive Ironwood Pharmaceuticals's (NASDAQ:IRWD) Share Price Down By 41%?
  6. Ironwood Pharmaceuticals to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference
  7. See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
  8. Ironwood (IRWD) Q1 Earnings & Revenues Miss, Shares Fall
  9. Ironwood Pharmaceuticals Inc (IRWD) Q1 2019 Earnings Call Transcript
  10. Did Hedge Funds Drop The Ball On Ironwood Pharmaceuticals, Inc. (IRWD) ?
  11. Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
  12. Ironwood: 1Q Earnings Snapshot
  13. Ironwood Pharmaceuticals Reports First Quarter 2019 Results; Announces Positive 2019 Adjusted EBITDA from Continuing Operations Guidance
  14. Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  15. Ironwood Pharmaceuticals to Host First Quarter 2019 Investor Update Call
  16. Ironwood Pharmaceuticals Announces Adjustment of Conversion Rate for its 2.25% Convertible Senior Notes due 2020
  17. Will Ironwood Suffer From Dependence on Linzess' Progress?
  18. As Ironwood spinout Cyclerion launches on the Nasdaq, CEO Hecht sees 'a fresh start'
  19. Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company
  20. Ironwood's new CEO has big plans for Linzess, but is mum on R&D